Early Miscarriage Occurring Six Days After Intravitreal Ranibizumab Injection
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 8 No. 2 (2019),
15 June 2019
,
Page 69-72
Abstract
The aim of this case report was to describe a miscarriage which occurred 6 days after an intravitreal Ranibizumab (IVR) injection. A 24-year-old female patient with type 1 diabetes diagnosed with diabetic macular edema in her left eye planned for 3 injections of IVR at one-month intervals. She had been receiving insulin injections 3 times a day and her Hemoglobin A1C (HbA1c) was in the approximate range of 6–7%. An ophthalmologic examination revealed that the patient’s Snellen corrected distance visual acuity (CDVA) was 10/10 in her right eye and 3/10 in her left eye. The patient was unaware of her pregnancy at the time of initial injection. Two days after the first injection, she found out that she was 5 weeks pregnant. This was the first pregnancy for the patient and there were no risk factors for miscarriage rather than diabetes. Six days after the injection, she was admitted to the hospital due to severe abdominal pain and vaginal bleeding. Miscarriage was diagnosed and she underwent curettage procedure. We concluded that pregnancy tests should be administered prior to intravitreal injection for female patients of reproductive age, and patient testimony should not be the sole reason to dismiss the possibility of pregnancy.Â
References
Kim H, Lee K, Lee CS, Byeon SH, Lee SC. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Retina. 2015;35(3):481-6. doi: 10.1097/IAE.0000000000000354 pmid: 25313710
Polizzi S, Mahajan VB. Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature. J Ocul Pharmacol Ther. 2015;31(10):605-10. doi: 10.1089/jop.2015.0056 pmid: 26302032
Granger JP. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension. 2009;54(3):465-7. doi: 10.1161/HYPERTENSIONAHA.109.132274 pmid: 19652083
Meyer CH, Ziemssen F, Heimann H. [Intravitreal injection. Monitoring to avoid postoperative complications]. Ophthalmologe. 2008;105(2):143-55, 57. doi: 10.1007/s00347-008-1701-7 pmid: 18256842
Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014;28(4):492-4. doi: 10.1038/eye.2013.311 pmid: 24434664
Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod. 2013;28(10):2628-35. doi: 10.1093/humrep/det308 pmid: 23900206
Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009;22(5):371-8. doi: 10.1080/14767050802645035 pmid: 19529993
Peracha ZH, Rosenfeld PJ. Anti-Vascular Endothelial Growth Factor Therapy in Pregnancy: What We Know, What We Don't Know, and What We Don't Know We Don't Know. Retina. 2016;36(8):1413-7. doi: 10.1097/IAE.0000000000001200 pmid: 27388726
Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res. 2014;39(5):518-21. doi: 10.3109/02713683.2013.848899 pmid: 24215127
Lucentis((R)) (ranibizumab) ABBREVIATED UK PRESCRIBING INFORMATION. Eye (Lond). 2017;31(S2):S18-S20. doi: 10.1038/eye.2017.149 pmid: 28845845
Fossum P, Couret C, Briend B, Weber M, Lagarce L. Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases. Eye (Lond). 2018;32(4):830-2. doi: 10.1038/eye.2017.305 pmid: 29350689
Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136. doi: 10.1111/j.1755-3768.2009.01572.x pmid: 19740128
Gomez Ledesma I, de Santiago Rodriguez MA, Follana Neira I, Leon Garrigosa F. [Neovascular membrane and pregnancy. Treatment with bevacizumab]. Arch Soc Esp Oftalmol. 2012;87(9):297-300. doi: 10.1016/j.oftal.2011.09.011 pmid: 22824650
Ford HB, Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009;2(2):76-83. pmid: 19609401
- Abstract Viewed: 937 times
- Free Full Text PDF Downloaded: 722 times
